Neuro 3d's €31.5 million third round late in 2004 was one of France's largest private biotech financings for years. But none of the investors are looking to France to provide the exit opportunities, which are more likely to be found in M&A, or in Switzerland.

Neuro 3d's €31.5 million third round late in 2004 was one of France's largest private biotech financings for years. But none of the investors are looking to France to provide the exit opportunities, which are more likely to be found in M&A, or in Switzerland.

Summarizing the month in European dealmaking.

"Insects represent three times the biodiversity of plants and microorganisms put together, " says Mario Thomas, PhD, CEO of Entomed SA. That's why Entomed is hopeful that insect genes will help it discover novel anti-infectives and other drugs.